The collaboration follows a partnership between AbbVie and Neomorph in January 2025, focusing on the development of molecular glue degraders. The treatments are intended for use in oncology and ...
The announcement comes less than a month after AbbVie partnered with Neomorph to develop new drug candidates for multiple targets across oncology and immunology in a deal worth $1.64bn. The ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. This time, the pharma is paying Xilio Therapeutics $52 million upfront to work on antibody-based ...
NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into... ByInvesting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback